Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

DBC Research USA Corp

Neither a doctor nor a teaching hospital

Research payments

$2,972,568

163 payments

Through program year 2025, DBC Research USA Corp is reported as receiving $2,972,568 in research payments, across 163 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $136,603 9
2024 Research $1,185,181 38
2023 Research $512,715 56
2022 Research $608,717 44
2021 Research $501,412 10
2020 Research $27,940 6

Breakdown

Who paid Research payments · program years 2020–2025
  1. Pfizer Inc. $2,604,464 144 payments
  2. Becton, Dickinson and Company $310,399 5 payments
  3. AbbVie, Inc. $29,765 8 payments
  4. Adare Pharmaceuticals, Inc. $27,940 6 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $815,774 34 payments
  2. A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety Tolerability Immunogenicity and Immunopersistence of A Clostridioides Difficile Vaccine Administered in A 2Dose Regimen With Novel Adjuvants in Healthy Adults $564,439 33 payments
  3. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $492,075 17 payments
  4. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $353,197 26 payments
  5. VerFresh $207,629 3 payments
  6. A Phase 12 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza in Healthy Individuals $181,304 7 payments
  7. A Phase 1 Randomized Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Modified Rna Vaccine Candidates Against Covid19 and Influenza in Healthy Individuals $146,370 19 payments
  8. Maxmm2 $85,642 1 payment
  9. A Phase 2B Doubleblind Randomized Placebocontrolled Parallel Group Dose Ranging Study to Evaluate Virological Response and Safety of Oral Pf07817883 in Nonhospitalized Symptomatic Adult Participants With Covid19 $39,305 7 payments
  10. Efficacy and Safety APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) $27,940 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record